TY - JOUR
T1 - Comparing the association between multiple chronic conditions, multimorbidity, frailty, and survival among older patients with cancer
AU - Bensken, Wyatt P.
AU - Schiltz, Nicholas K.
AU - Warner, David F.
AU - Kim, Dae H.
AU - Wei, Melissa Y.
AU - Quiñones, Ana R.
AU - Ho, Vanessa P.
AU - Kelley, Amy S.
AU - Owusu, Cynthia
AU - Kent, Erin E.
AU - Koroukian, Siran M.
N1 - Funding Information:
Dr. Owusu is supported by grants from the National Institute of Minority Health and Health Disparities ( R01 MD009699 ) and the National Cancer Institute ( R25 CA22178A , 1P20CA233216–01 ).
Funding Information:
This study was funded by the Case Comprehensive Cancer Center ( P30 CA043703 ).
Funding Information:
Dr. Kim is supported by grants R01AG071809 , R01AG062713 , R01AG056368 , and R21AG060227 from the National Institute on Aging . Dr. Kim receives personal fees from Alosa Health and VillageMD.
Funding Information:
Dr. Wei was supported by the National Institutes of Health, National Institute on Aging (grant K23AG056638 ).
Funding Information:
Dr. Ho is supported by the Clinical and Translational Science Collaborative of Cleveland , KL2TR002547 from the National Center for Advancing Translational Sciences (NCATS) component of the National Institutes of Health and NIH roadmap for Medical Research .
Funding Information:
Dr. Koroukian, in the past 36 months, was supported by grants from the: National Cancer Institute, Case Comprehensive Cancer Center ( P30 CA043703 ); Centers for Disease Control and Prevention , U48 DP005030-05S1 and U48 DP006404-03S7 ; Ohio Medicaid Technical Assistance and Policy Program (MEDTAPP); National Institutes of Health ( R15 NR017792 , and UH3-DE025487 ); The American Cancer Society ( 132,678-RSGI-19-213-01-CPHPS and RWIA-20-111-02 RWIA ); and by contracts from Cleveland Clinic Foundation , including a subcontract from Celgene Corporation . Dr. Koroukian's spouse has stock ownership in American Renal Associates, Inc.
Funding Information:
Mr. Bensken is supported by a grant from the National Institute of Minority Health and Health Disparities ( 1F31MD015681 ).
Funding Information:
Dr. Warner was supported by grants from the National Cancer Institute , Case Comprehensive Cancer Center ( P30 CA043703 ) and the Centers for Disease Control and Prevention ( 3 U48 DP006404-03S7 ). This research was also supported in part by the Center for Family and Demographic Research , Bowling Green State University , which has core funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development ( P2CHD050959 ).
Funding Information:
Dr. Kelley is supported by the National Institute on Aging (NIA K24 AG062785).
Publisher Copyright:
© 2022 Elsevier Ltd
PY - 2022/11
Y1 - 2022/11
N2 - Introduction: The high prevalence of multiple chronic conditions (MCC), multimorbidity, and frailty may affect treatment and outcomes for older adults with cancer. The goal of this study was to use three conceptually distinct measures of morbidity to examine the association between these measures and mortality. Materials and Methods: Using Medicare claims data linked with the 2012–2016 Ohio Cancer Incidence Surveillance System we identified older adults with incident primary cancer sites of breast, colorectal, lung, or prostate (n = 29,140). We used claims data to identify their Elixhauser comorbidities, Multimorbidity-Weighted Index (MWI), and Claims Frailty Index (CFI) as measures of MCC, multimorbidity, and frailty, respectively. We used Cox proportional hazard models to examine the association between these measures and survival time since diagnosis. Results: Lung cancer patients had the highest levels of MCC, multimorbidity, and frailty. There was a positive association between all three measures and a greater hazard of death after adjusting for age, sex (colorectal and lung only), and stage. Breast cancer patients with 5+ comorbidities had an adjusted hazard ratio (aHR) of 1.63 (95% confidence interval [CI]: 1.38, 1.93), and those with mild frailty had an aHR of 3.38 (95% CI; 2.12, 5.41). The C statistics for breast cancer were 0.79, 0.78, and 0.79 for the MCC, MWI, and CFI respectively. Similarly, lung cancer patients who were moderately or severely frail had an aHR of 1.82 (95% CI: 1.53, 2.18) while prostate cancer patients had an aHR of 3.39 (95% CI: 2.12, 5.41) and colorectal cancer patients had an aHR of 4.51 (95% CI: 3.23, 6.29). Model performance was nearly identical across the MCC, multimorbidity, and frailty models within cancer type. The models performed best for prostate and breast cancer, and notably worse for lung cancer. The frailty models showed the greatest separation in unadjusted survival curves. Discussion: The MCC, multimorbidity, and frailty indices performed similarly well in predicting mortality among a large cohort of older cancer patients. However, there were notable differences by cancer type. This work highlights that although model performance is similar, frailty may serve as a clearer indicator in risk stratification of geriatric oncology patients than simple MCCs or multimorbidity.
AB - Introduction: The high prevalence of multiple chronic conditions (MCC), multimorbidity, and frailty may affect treatment and outcomes for older adults with cancer. The goal of this study was to use three conceptually distinct measures of morbidity to examine the association between these measures and mortality. Materials and Methods: Using Medicare claims data linked with the 2012–2016 Ohio Cancer Incidence Surveillance System we identified older adults with incident primary cancer sites of breast, colorectal, lung, or prostate (n = 29,140). We used claims data to identify their Elixhauser comorbidities, Multimorbidity-Weighted Index (MWI), and Claims Frailty Index (CFI) as measures of MCC, multimorbidity, and frailty, respectively. We used Cox proportional hazard models to examine the association between these measures and survival time since diagnosis. Results: Lung cancer patients had the highest levels of MCC, multimorbidity, and frailty. There was a positive association between all three measures and a greater hazard of death after adjusting for age, sex (colorectal and lung only), and stage. Breast cancer patients with 5+ comorbidities had an adjusted hazard ratio (aHR) of 1.63 (95% confidence interval [CI]: 1.38, 1.93), and those with mild frailty had an aHR of 3.38 (95% CI; 2.12, 5.41). The C statistics for breast cancer were 0.79, 0.78, and 0.79 for the MCC, MWI, and CFI respectively. Similarly, lung cancer patients who were moderately or severely frail had an aHR of 1.82 (95% CI: 1.53, 2.18) while prostate cancer patients had an aHR of 3.39 (95% CI: 2.12, 5.41) and colorectal cancer patients had an aHR of 4.51 (95% CI: 3.23, 6.29). Model performance was nearly identical across the MCC, multimorbidity, and frailty models within cancer type. The models performed best for prostate and breast cancer, and notably worse for lung cancer. The frailty models showed the greatest separation in unadjusted survival curves. Discussion: The MCC, multimorbidity, and frailty indices performed similarly well in predicting mortality among a large cohort of older cancer patients. However, there were notable differences by cancer type. This work highlights that although model performance is similar, frailty may serve as a clearer indicator in risk stratification of geriatric oncology patients than simple MCCs or multimorbidity.
KW - Frailty
KW - Multimorbidity
KW - Multiple chronic conditions
KW - Older adults
UR - http://www.scopus.com/inward/record.url?scp=85133333762&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85133333762&partnerID=8YFLogxK
U2 - 10.1016/j.jgo.2022.06.011
DO - 10.1016/j.jgo.2022.06.011
M3 - Article
C2 - 35786369
AN - SCOPUS:85133333762
SN - 1879-4068
VL - 13
SP - 1244
EP - 1252
JO - Journal of Geriatric Oncology
JF - Journal of Geriatric Oncology
IS - 8
ER -